Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy

Executive Summary

Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
Advertisement

Related Content

With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Bristol Recharges Kai Heart Attack Candidate
Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Advertisement
UsernamePublicRestriction

Register

PS048835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel